Search research articles
Contact Us
Filters
Showing results (11-20 of 22) with videos related to
Page
of 3
Sort By:
Frontiers in Immunology
|
June 7, 2024
Mathematical modelling of stem and progenitor cell dynamics during ruxolitinib treatment of patients with myeloproliferative neoplasms
Tobias Idor Boklund, Jordan Snyder, Johanne Gudmand-Hoeyer, et al.
Current Oncology (Toronto, Ont.)
|
March 27, 2026
Maintenance Strategies in High-Risk Myeloma: A Multicenter Comparison of Bortezomib-Lenalidomide Versus Lenalidomide Alone: A USMIRC Multicenter Analysis
Sruthi P Ramanan, Oyepeju F Abioye, Shebli Atrash, et al.
Blood Cancer Journal
|
March 4, 2025
Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma
James A Davis, Jordan Snyder, Mikhaila Rice, et al.
Cancers
|
November 13, 2025
Teclistamab Dosing Strategies in Relapsed/Refractory Myeloma: A Real-World Comparison of Weekly and Biweekly Versus Fixed Intervals
Jordan Snyder, Shebli Atrash, Barry Paul, et al.
Nature Genetics
|
February 16, 2026
Modeling the evolutionary dynamics of clonal hematopoiesis
Sadegh Marzban, Thomas Stiehl, Zhuoer Xie, et al.
Frontiers in Oncology
|
May 24, 2023
Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis
Lasse Kjær, Vibe Skov, Morten Kranker Larsen, et al.
Current Oncology (Toronto, Ont.)
|
May 26, 2026
Outcomes of Double-Hit and Single High-Risk Cytogenetic Newly Diagnosed Myeloma in Transplant-Eligible Patients
Raeef Rahman, Anas Zayad, Carmel Awadallah, et al.
Cancers
|
March 14, 2026
A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment-USMIRC Group
Maha Hameed, Alma Habib, Abdullah Mohammad Khan, et al.
Blood Neoplasia
|
April 20, 2026
Safety of MMR vaccination for patients with myeloma receiving daratumumab after autologous stem cell transplantation
James A Davis, Jessica McElwee, Rebecca Gonzalez, et al.
American Journal of Hematology
|
June 16, 2026
Dexamethasone for Management of Cytokine Release Syndrome Associated With Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma
Jessica McElwee, Grace Elsey, Rebecca Gonzalez, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 22) with videos related to
Sort By:
Page
of 3
Frontiers in Immunology
|
June 7, 2024
Mathematical modelling of stem and progenitor cell dynamics during ruxolitinib treatment of patients with myeloproliferative neoplasms
Tobias Idor Boklund, Jordan Snyder, Johanne Gudmand-Hoeyer, et al.
Current Oncology (Toronto, Ont.)
|
March 27, 2026
Maintenance Strategies in High-Risk Myeloma: A Multicenter Comparison of Bortezomib-Lenalidomide Versus Lenalidomide Alone: A USMIRC Multicenter Analysis
Sruthi P Ramanan, Oyepeju F Abioye, Shebli Atrash, et al.
Blood Cancer Journal
|
March 4, 2025
Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma
James A Davis, Jordan Snyder, Mikhaila Rice, et al.
Cancers
|
November 13, 2025
Teclistamab Dosing Strategies in Relapsed/Refractory Myeloma: A Real-World Comparison of Weekly and Biweekly Versus Fixed Intervals
Jordan Snyder, Shebli Atrash, Barry Paul, et al.
Nature Genetics
|
February 16, 2026
Modeling the evolutionary dynamics of clonal hematopoiesis
Sadegh Marzban, Thomas Stiehl, Zhuoer Xie, et al.
Frontiers in Oncology
|
May 24, 2023
Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis
Lasse Kjær, Vibe Skov, Morten Kranker Larsen, et al.
Current Oncology (Toronto, Ont.)
|
May 26, 2026
Outcomes of Double-Hit and Single High-Risk Cytogenetic Newly Diagnosed Myeloma in Transplant-Eligible Patients
Raeef Rahman, Anas Zayad, Carmel Awadallah, et al.
Cancers
|
March 14, 2026
A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment-USMIRC Group
Maha Hameed, Alma Habib, Abdullah Mohammad Khan, et al.
Blood Neoplasia
|
April 20, 2026
Safety of MMR vaccination for patients with myeloma receiving daratumumab after autologous stem cell transplantation
James A Davis, Jessica McElwee, Rebecca Gonzalez, et al.
American Journal of Hematology
|
June 16, 2026
Dexamethasone for Management of Cytokine Release Syndrome Associated With Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma
Jessica McElwee, Grace Elsey, Rebecca Gonzalez, et al.
Page
of 3